Navigation Links
Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
Date:7/23/2008

Investor Also Agrees to Increase Original Warrant Amount by an Additional

$44.5 million

SEATTLE, July 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) today announced that a single institutional investor has agreed to purchase, for $44.5 million, newly issued 18.33% Convertible Senior Notes due 2011, with a conversion price of $0.79 per share, and a warrant to purchase approximately 28.2 million shares of common stock with an exercise price of $0.79 per share. Of such amount, $22.25 million will be funded this week and the remaining $22.25 million must be funded prior to August 25, 2008. Additionally, the agreement provides for the further amendment of the original warrant right which would be exercisable for an additional $44.5 million of units to the investor under the same terms if both parties agree to do so and subject to additional filings with the Nasdaq Stock Market.

This transaction constitutes an exercise of a previously granted warrant right for the investor to purchase up to $67.5 million of such unit securities. The Company and the investor have amended their original April 2008 agreements and subsequent amendment to change from 15.0% to 18.33% the interest rate on the Notes within these units being issued in July and August, and to reduce from $0.95 to $0.79 the per share exercise price of all common stock warrants arising from the April 2008 agreements and subsequent exercises, but the purchase price for the securities and the conversion price of the notes remain unchanged. The Company has also agreed to repurchase from the investor an aggregate amount of $17.5 million of outstanding 13.5% Convertible Senior Notes, of which half are being repurchased in connection with this July transaction and the other half will be repurchased in connection with the subsequent exercise prior to August 25, 2008. Warrants to purchase approximately 11 million shares of common stock which were
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
2. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
3. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
4. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
5. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
6. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
7. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
9. Cell Therapeutics, Inc. (CTI) to Report 2008 First Quarter and Financial Results on May 8
10. Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
11. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Calif. , Sept. 30, 2014 FemCap ... women,s health announces its receipt of a patent No: ... menstrual cup has also received FDA clearance in the ... and the CE in Europe. This patent is related to ... with this issuance, the company is releasing FemmyCycle Teen, ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Lyme ... funder of Lyme disease research at universities, today announced ... focused on the identification, treatment and cure for Lyme ... had received the most applications in its history—over 20 ... , “While we were pleased to receive so many ...
(Date:9/30/2014)... UFP Technologies, a producer of ... recently introduced a custom insulated shipping container to ... new insulated shipper solves the issue of temperature ... Technologies’ BioShell is a universal storage container which ... and shipping. The insulated shipper keeps frozen BioShells ...
(Date:9/29/2014)... Each year in the US, ... attention. In the military, burn injury is a ... medical care. More than 800 service members sustained ... heal slowly, remain inflamed and often become infected, ... and functionally damaging. While developments in supportive care ...
Breaking Biology Technology:The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 2UFP Technologies Introduces Insulated Shipping Container For Bulk Drug Transportation 3Faster Healing with Fewer Scars 2
... , ... ... ... ...
... ... with a Complete, Cloud-Enabled API for Developers , ... Westborough, Mass. (Vocus) March 4, 2010 -- This seminar details the fast-growing ... The free seminar will include lunch, discussion, and startup to Free Basic Account. , ...
... ... ... ... ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 2OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009 3GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32
(Date:9/30/2014)... Having trouble getting pregnanteven with IVF? Here,s some hope: ... of The FASEB Journal , explains ... protein known as PAWP, which induced embryo development in ... of embryo development by the sperm cell during fertilization. ... represent a major paradigm shift in our understanding of ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
(Date:9/29/2014)... species of gut bacteria called Clostridium ramosum , coupled ... The work is published this week in mBio , ... , A research team from the German Institute of ... gut bacteria including C. ramosum gained weight when ... C. ramosum were less obese even when consuming a ...
Breaking Biology News(10 mins):Synthetic sperm protein raises the chance for successful in vitro fertilization 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2
... varies dramatically according to whether the nurses leave the ... airflow in a "Nightingale" warda classic hospital ward design ... bedsby using tracer gases to simulate how airborne infections ... generally good when windows were left open, keeping the ...
... Male circumcision reduces the abundance of bacteria living on the ... protection against HIV, according to a study led by the ... a significant shift in the bacterial community or microbiome of ... online journal mBio . This international collaboration focused ...
... What do woolly mammoths wandering around the ancient ... do with predicting how species could respond to ... Maryland Center for Environmental Science,s Appalachian Laboratory, along ... the University of California-Merced, have received a three-year, ...
Cached Biology News:Energy efficiency could increase infection risks in hospital wards 2Energy efficiency could increase infection risks in hospital wards 3TGen-led study discovers dramatic changes in bacteria following male circumcision 2Scientists look to ancient past to better predict how species may respond climate change 2
SHEEP ANTI FLECAINIDE...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
... are ideal for use in refrigerators, freezers, or liquid ... vibrant colors allow for color coding to project, user, ... drainage or promote cool air circulation. Supplied with 10 ... tubes. Box dimensions: 13 x 13 x ...
RABBIT ANTI BACTERIAL HISTIDASE...
Biology Products: